ClinicalTrials.gg
TerminatedNCT00051584Updated Oct 24, 2011

Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer

A Phase 2 interventional study of SGN-15 (cBR96-Doxorubicin Immunoconjugate) and Gemzar (Gemcitabine) in Ovarian Neoplasms, sponsored by Seagen Inc.. Terminated at 6 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-10-24.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 40 studies testing gemcitabine in Ovarian Neoplasms — none open to participants now, 2 under way, 1 of them phase 3. Gemcitabine · Ovarian Neoplasms.

Enrollment
11th of 34
60 · median 39
Phase 2
21 of 40
none open now
Registered
12th of 40
by date

Among the 40 studies testing gemcitabine in Ovarian Neoplasms, this one is the 11th largest by enrollment of the 34 interventional ones that give a count, is one of 21 in phase 2, and was the 12th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 40 studies testing gemcitabine in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing gemcitabine in Ovarian Neoplasms as a file.
02

Study summary

This is an open-label, randomized phase II trial comparing treatment with a monoclonal antibody (mAb) drug immunoconjugate, SGN-15, administered weekly in combination with weekly Gemzar® (Gemcitabine) to treatment with Gemzar® alone. The primary objectives of this study are to determine the toxicity and safety profile of the combination of SGN-15 and Gemzar®, to estimate the clinical response rate and to estimate the duration of response of this combination therapy administered to patients with advanced ovarian cancer, compared to treatment with Gemzar® alone.

03

Conditions studied

  • Ovarian Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Brief Overview of Inclusion Criteria:

  • Patients must have confirmed ovarian cancer, which is advanced or recurrent carcinoma, who have failed at least two, but no more than three prior therapies for disease
  • Patients must have > 20% Lewis-y antigen expression documented by immunohistochemistry
  • > 50% by echo or MUGA
  • Must be platinum resistant as defined by:

    • Progression while on initial platinum therapy or
    • Progression while on retreatment with initial platinum regimen or
    • Relapse \< 6 months after initial therapy

Brief Overview of Exclusion Criteria:

  • Patients who have had prior therapy with Gemzar®
  • Cumulative anthracycline exposure > 300 mg/m2
  • More than three prior chemotherapy regimens for ovarian cancer (Retreatment with Taxane/Platinum after initial combination is considered only one regimen)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants
06

Study locations

6 sites
  • Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • Sharp Healthcare
    San Diego, California 92123, United States
  • California Hematology Oncology Medical Group
    Torrance, California 90505, United States
  • Mountain States Tumor Institute
    Boise, Idaho 83712, United States
  • Arlington Fairfax Hematology Oncology
    Arlington, Virginia 22205, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00051584
Lead sponsor
Seagen Inc.
First posted
Jan 15, 2003
Completion
May 2003
Last update
Oct 24, 2011

Study contacts

Andrew Sandler, MD
study director · Seagen Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BR96-Doxorubicin Immunoconjugate · Gemcitabine

Start the discussion